P5-14-22: Prospective Observational Study To Describe the Clinicopathological and Biological Characteristics and the Management of Metastatic Breast Cancer Patients Who Experienced Complete or Partial Remission or Disease Stabilization during at Least 3 Years.

2011 ◽  
Author(s):  
P Zamora ◽  
R Pérez-Carrión ◽  
L Manso ◽  
C Crespo ◽  
C Mendiola ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Observational Study ◽  
Cancer Patients ◽  
Partial Remission ◽  
Prospective Observational Study ◽  
Metastatic Breast ◽  
Biological Characteristics ◽  
Breast Cancer Patients ◽  
Disease Stabilization

The Prognostic Significance of Increasing Marker Levels in Metastatic Breast Cancer Patients with Clinically Complete Remission, Partial Remission or Stable Disease

1998 ◽  
Vol 13 (1) ◽  
pp. 10-15 ◽  
Author(s):  
A. Van Dalen ◽  
V. Barak ◽  
A. Cremaschi ◽  
M. Gion ◽  
R. Molina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Complete Remission ◽  
Cancer Patients ◽  
Stable Disease ◽  
Partial Remission ◽  
Lead Time ◽  
Metastatic Breast ◽  
Breast Cancer Patients

TPS, CA 15-3 and CEA were determined in metastatic breast cancer patients during treatment. After six months of follow-up the patients were divided into four groups according to the UICC criteria for treatment response. Forty-six patients with a more favorable prognosis (complete remission, partial remission or stable disease) were followed for an extended period. In 30 of the 46 patients at least one marker had increased at the end of the six-month period by at least 25% (TPS in 54%, CA 15-3 in 20%, CEA in 20%). All these 30 patients subsequently developed progression. The prognostic sensitivity was 83%, 30% and 30%, respectively, for TPS, CA 15-3 and CEA. The combination of TPS and CA 15-3 showed a sensitivity of 96%. The median lead time was about 8 months for TPS and CA 15-3, but less than 50% of the patients showed a lead time for CA 15-3 as compared to TPS. We conclude that TPS and CA 15-3 determinations are helpful for the prediction of progression during the follow-up of breast cancer patients.

ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study

2017 ◽  
Vol 13 (17) ◽  
pp. 1517-1525 ◽  
Author(s):  
Luca Moscetti ◽  
Lucia Mentuccia ◽  
Patrizia Vici ◽  
Silvia Quadrini ◽  
Isabella Sperduti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Observational Study ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document